Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

<p>Addition of gemtuzumab ozogamicin (GO) to induction chemotherapy improves outcomes in older patients with acute myeloid leukemia (AML), but it is uncertain whether a fractionated schedule provides additional benefit to a single dose. We randomized 852 older adults (median age, 68-years) wit...

Full description

Bibliographic Details
Main Authors:	Freeman, SD, Thomas, A, Thomas, I, Hills, RK, Vyas, P, Gilkes, AF, Metzner, M, Jakobsen, NA, Kennedy, A, Moore, AR, Marquez-Almuina, N, Burns, S, King, S, Andrew, G, Gallagher, KME, Sellar, RS, Cahalin, PA, Weber, D, Dennis, M, Mehta, P, Knapper, S, Russell, NH
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2023

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

Similar Items